Tubulin polymerisation inhibitor
Tirbanibulin
Brand names: Klisyri
Adult dose
Dose: Apply 1% ointment to affected area OD x5 days
Route: Topical
Frequency: OD x5 days
Clinical pearls
- Actinic keratosis on face/scalp
- Avoid eye/lip; sun protection
Contraindications
- Hypersensitivity
- Mucosal/eye contact
Side effects
- Local skin reactions (erythema, scaling, crusting)
- Application-site pain
- Pruritus
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/tirbanibulin/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD